Cargando…

P15-11. Preventive HIV vaccine acceptability: a systematic review and meta-analysis

Detalles Bibliográficos
Autores principales:	Newman, PA, Logie, C
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767707/ http://dx.doi.org/10.1186/1742-4690-6-S3-P212

Ejemplares similares

Meta-analysis of correlates of HPV vaccine acceptability among men: supporting vaccine implementation science
por: Newman, PA, et al.
Publicado: (2012)

P15-10. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand
por: Newman, PA, et al.
Publicado: (2009)

P15-01. Willingness to participate in actual preventive HIV vaccine phase I/IIa trial in Bangkok, Thailand
por: Hemachandra, A, et al.
Publicado: (2009)

P15-23. Community engagement strategies in the Canadian HIV vaccine initiative
por: Milsom, P, et al.
Publicado: (2009)

P15-27. Community involvement and ethics in HIV vaccine trial in Nigeria
por: Adeyemi, AO, et al.
Publicado: (2009)

HPV vaccine acceptability among men: a systematic review and meta-analysis
por: Newman, Peter A, et al.
Publicado: (2013)

P15-26. Leveraging motivators to participation in HIV vaccine research in the age of Obama
por: Alexander, SB, et al.
Publicado: (2009)

P15-09. The potential global market size and public health value of hypothetical HIV-1 preventive vaccines with different levels of efficacy
por: Marzetta, CA, et al.
Publicado: (2009)

P15-18. Behavioral and social science in HIV vaccine clinical research: workshop recommendations
por: Lau, C, et al.
Publicado: (2009)

P15-20. Developing a national policy agenda for the Canadian HIV vaccine initiative
por: Sarazin, V, et al.
Publicado: (2009)

P15-22. Potential synergies between HIV vaccines, microbicides and pre-exposure prophylaxis
por: Sarazin, V, et al.
Publicado: (2009)

P14-11. Educating community medical providers about HIV vaccine induced seropositivity
por: Mark, KE, et al.
Publicado: (2009)

P17-11. HIV DNA vaccine delivery in association with electroporation in the skin of nonhuman primates
por: Culina, S, et al.
Publicado: (2009)

P11-18. Immunogenicity of Lactobacillus gasseri-FliC as an oral mucosal vaccine adjuvant for HIV
por: Gunderson, S, et al.
Publicado: (2009)

P15-21. Investigating the utility and relevance of the good participatory practice guidelines for biomedical HIV prevention trials
por: Miller, L, et al.
Publicado: (2009)

A social ecological model of willingness to participate in HIV vaccine trials among men who have sex with men in Chennai and Mumbai, India
por: Chakrapani, V, et al.
Publicado: (2012)

P15-28. Attitudes and awareness of HIV vaccine research in HIV uninfected MSM in four US cities: Rochester, Boston, San Francisco and Philadelphia
por: Alexander, SB, et al.
Publicado: (2009)

P15-19. Evaluating community engagement efforts in a large, multi-site, global HIV vaccine trials network
por: Maggard, K, et al.
Publicado: (2009)

P06-09. Web based interviewing system for HIV-behavior research in the settings of vaccine and non vaccine prevention trials
por: Peinado, JE, et al.
Publicado: (2009)

P15-17. Social media as a tool for engaging and educating audiences around HIV vaccine research and clinical trial participation
por: Sitar, S, et al.
Publicado: (2009)

P15-25. Preparation for HIV vaccine trials in Africa: barriers and facilitators for the establishment of a community advisory board in Burkina Faso
por: Berthe, A, et al.
Publicado: (2009)

P19-15. Synthesis of multivalent mimotopes as potential vaccine candidates
por: Go, JG, et al.
Publicado: (2009)

Audit of telephone HIV clinics: effective and acceptable
por: Woolley, WFC, et al.
Publicado: (2010)

P15-03. HIV vaccine funding trends entering a global recession: research and development (R&D) from 2000 – 2008
por: Fisher, K, et al.
Publicado: (2009)

P15-05. Evaluation and recommendations on good clinical laboratory practice (GCLP) guidelines for phase I-III HIV vaccine clinical trials
por: Sarzotti-Kelsoe, M, et al.
Publicado: (2009)

P15-30 LB. An evaluation of prescreen recruitment data: enrolling racial/ethnic minorities in Phase I HIV vaccine clinical trials
por: Johnson, D, et al.
Publicado: (2009)

P11-15. Induction of a mucosal immune response to HIV after systemic immunization with poly(lactic acid) nanoparticles formulated with gag antigen and polyI:C
por: Primard, C, et al.
Publicado: (2009)

P14-15 LB. The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in phase I clinical trial
por: Shao, Y, et al.
Publicado: (2009)

P15-06. Brighton collaboration viral vector vaccines safety working group (V3SWG): maximizing the comparability and value of safety data from HIV vaccine trials
por: Chen, RT, et al.
Publicado: (2009)

P14-07. Offering new prevention modalities in HIV vaccine trials: experience with male circumcision in the Phambili trial
por: de Bruyn, G, et al.
Publicado: (2009)

P15-07. Knowledge, attitudes, practices and willingness to participate in HIV vaccine trials among urban residents of Bamako, Mali, in West Africa, 2005–2009
por: Tounkara, K, et al.
Publicado: (2009)

P15-14. Assuring data quality of the phase III vaccine trial of ALVAC vaccine priming and AIDSVAX vaccine boosting in Thailand
por: Kaewkungwal, J, et al.
Publicado: (2009)

P19-25. A vaccine model to prevent the depletion of uninfected bystander CD4 cells during HIV infection
por: Vieillard, V, et al.
Publicado: (2009)

P11-03. Mucosal trafficking and differentiation of vaccine-elicited CD8+ T-lymphocytes
por: Kaufman, DR, et al.
Publicado: (2009)

P12-15. Replication enhancement of an alphaviral-lentiviral replicating chimeric particle (RCP) vaccine
por: Young, K, et al.
Publicado: (2009)

P04-15. Prevalence of broadly neutralizing antibody responses during acute/early HIV infection
por: Mikell, I, et al.
Publicado: (2009)

P14-09. Use of HIV rapid tests for assessment of persistence of vaccine induced antibodies among HIV vaccine recipients
por: Karita, E, et al.
Publicado: (2009)

P06-08. Building an African HIV preventive trial network
por: Price, MA, et al.
Publicado: (2009)

P17-15. Immunogenicity studies of chimeric yellow fever 17D viruses carrying HIV-1 p24 antigen
por: Franco, D, et al.
Publicado: (2009)

P035. Headache prevalence and disability among Italian adolescents aged 11-15 years: a population cross-sectional study
por: Maffioletti, Erika, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uf97q3d46v0uka2kc404ul5ocd